Burning Rock Biotech Limited Q1 Loss Rises

Burning Rock Biotech (NASDAQ: BNR) reported Q2 2026 revenues of RMB134.7M (US$19.9M), down 9.3% YoY. Central lab revenue fell 10%, while in-hospital revenue rose 7.4%. Gross profit decreased 9.5% to RMB97.8M. The company expects new product approvals to drive future growth. Cash reserves stood at RMB419.1M as of June 30, 2026.

Burning Rock Biotech Ltd (BNR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Burning Rock Reports Second Quarter 2026 Financial Results GUANGZHOU, China, September 10, 2026—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the fie

Infosys (INFY) cut its FY27 revenue growth forecast to 1%-2% from 1.5%-3%, citing weak North America demand. Shares fell 2.7% on the news. Q2 net income was 78.2B rupees, slightly below estimates. The company attributes the downgrade to clients reducing large IT projects.

Dr. Reddy's Laboratories' shares rose 3.18% to Rs 1,268.60 despite a 36% YoY profit decline to Rs 913.4 crore in Q2. Revenue fell 1.5% to Rs 8,671 crore. Brokerages offered mixed outlooks, with targets ranging from Rs 1,270 to Rs 1,730, citing margin performance and upcoming product developments.

India's Sensex and Nifty 50 opened lower on Oct. 26 as oil prices eased. Brent crude fell 1.82% to $114.60. Infosys reported $5.145B revenue, with AI revenue up 29%. Kotak Mahindra Bank's profit rose 29% YoY. Dr. Reddy's revenue declined 1.5% YoY. FOMC meets Oct. 27-28.

Infosys shares fell 2.7% after cutting its fiscal 2027 revenue growth forecast to 1%-2% from 1.5%-3%, citing pricing pressure and weak tech spending. Analysts reduced price targets, with the average rating remaining 'Buy' and a median target of 1,180 rupees.